Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 315 of the 321 references it cites were found in a registry or an index; 69 of the 243 sources its claims cite were checked for support.

Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration

Open access

Abstract

The complement system is crucial for immune surveillance, providing the body’s first line of defence against pathogens. However, an imbalance in its regulators can lead to inappropriate overactivation, resulting in diseases such as age-related macular degeneration (AMD), a leading cause of irreversible blindness globally affecting around 200 million people. Complement activation in AMD is believed to begin in the choriocapillaris, but it also plays a critical role in the subretinal and retinal pigment epithelium (RPE) spaces. Bruch’s membrane (BrM) acts as a barrier between the retina/RPE and choroid, hindering complement protein diffusion. This impediment increases with age and AMD, leading to compartmentalisation of complement activation. In this review, we comprehensively examine the structure and function of BrM, including its age-related changes visible through in vivo imaging, and the consequences of complement dysfunction on AMD pathogenesis. We also explore the potential and limitations of various delivery routes (systemic, intravitreal, subretinal, and suprachoroidal) for safe and effective delivery of conventional and gene therapy-based complement inhibitors to treat AMD. Further research is needed to understand the diffusion of complement proteins across BrM and optimise therapeutic delivery to the retina.

Overview

CoChat Summary

TL;DR

This review argues that Bruch’s membrane (BrM) is a selectively permeable, age-changing barrier that compartmentalises complement activation in age-related macular degeneration (AMD) and complicates drug delivery to the retina. It evaluates systemic, intravitreal, subretinal, and suprachoroidal routes for complement inhibitors and gene therapies, concluding that further work is needed to understand and optimise transit across BrM.

Key findings

  • BrM is a 2–4 μm five-layer extracellular matrix between the RPE and choroid; its permeability declines with age, with one study reporting an almost 100% reduction in serum protein permeability from the first to ninth decades of life (from 3.5 × 10−6 to 0.2 × 10−6 cm/s), and a permeability threshold falling from >200 kDa in younger donors to 100 kDa in elderly donors.
  • Complement protein passage across BrM is selective: FHL-1, Factor D, and C5a can cross, whereas C3a is not able to despite its small molecular weight; C3/C3b, FH, FB, and FI are unable to penetrate BrM even at small quantities. FHL-1 (49 kDa) has better tissue penetration than full-length glycosylated FH (155 kDa).
  • AMD affects around 200 million people globally; 95% of cases are non-exudative. Genetic risk includes CFH p.Y402H, conferring approximately two-fold higher risk of late-stage AMD per allele, and GWASs have detected 52 independent and rare variants across 34 loci. Smoking is associated with an odds ratio of 1.78 (95% CI 1.52–2.09) for current versus ex-smokers.
  • Intravitreal complement inhibitors pegcetacoplan and avacincaptad pegol showed anatomical benefits for geographic atrophy at one year in Phase 3 studies, but visual outcome benefit remains unknown and both have safety concerns regarding induction of exudative AMD. Systemic eculizumab completed a randomised controlled trial in AMD but failed to show significant anatomical or functional benefit.

Methods

  • Narrative review synthesising literature on BrM structure and function, age-related changes, AMD pathogenesis, complement dysfunction, in vivo imaging, and therapeutic delivery routes.
  • Evidence base includes human tissue studies, animal and cell models, genetic and imaging studies, and clinical trial reports; no systematic search strategy, meta-analysis, or primary data collection is described.
  • Main analysis is qualitative synthesis, with tables and figures summarising age-related BrM changes and delivery approaches.

Limitations

  • Stated: further research is needed to understand diffusion of complement proteins across BrM and to optimise therapeutic delivery to the retina; diffusion chamber models may not fully capture human physiology; murine models have limitations for studying AMD; the effects of complete complement inhibition in the eye remain unclear.
  • Stated: the eculizumab AMD trial had limited treatment duration (6 months), a small sample size, and several methodological biases.
  • Evident: as a narrative review, it does not describe a systematic literature search or formal risk-of-bias assessment, and many conclusions rely on preclinical/animal models or early-phase and interim clinical data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/jcm12082870

Cites

315 of 315 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 3 Pathological changes at the BrM interface in AMD. In healthy individuals (top panels), the retinal tissues are in a state of metabolic equilibrium. Early/intermediate AMD (middle panels) is characterised by the accumulation of extracellular deposits (illustrated in orange), such as soft drusen/BLinDs beneath the RPE and subretinal drusenoid deposits above it. These deposits mainly consist of lipoproteins of dietary and photoreceptor outer segment origin and are excreted by the RPE. They accumulate in the sub-RPE space and impede transit to the choroid due to ageing of the Bruch’s membrane. The accumulation of these deposits is associated with underlying choriocapillaris vascular dropout and initiates an immune response that leads to the recruitment of inflammatory cells. These deposits increase the risk of advanced stages of AMD, including atrophy and neovascularisation (bottom panels). Notably, BrM is more visible in areas of RPE separation and choroidal neovascularisation (white arrows). Changes within the Bruch’s membrane are not depicted in this figure. Open-source images used with permission [88]. Abbreviations: AMD, age-related macular degeneration; BLinDs, basal linear deposits; BrM, Bruch’s membrane; RPE, retinal pigment epithelium.
Figure 3 Pathological changes at the BrM interface in AMD. In healthy individuals (top panels), the retinal tissues are in a state of metabolic equilibrium. Early/intermediate AMD (middle panels) is characterised by the accumulation of extracellular deposits (illustrated in orange), such as soft drusen/BLinDs beneath the RPE and subretinal drusenoid deposits above it. These deposits mainly consist of lipoproteins of dietary and photoreceptor outer segment origin and are excreted by the RPE. They accumulate in the sub-RPE space and impede transit to the choroid due to ageing of the Bruch’s membrane. The accumulation of these deposits is associated with underlying choriocapillaris vascular dropout and initiates an immune response that leads to the recruitment of inflammatory cells. These deposits increase the risk of advanced stages of AMD, including atrophy and neovascularisation (bottom panels). Notably, BrM is more visible in areas of RPE separation and choroidal neovascularisation (white arrows). Changes within the Bruch’s membrane are not depicted in this figure. Open-source images used with permission [88]. Abbreviations: AMD, age-related macular degeneration; BLinDs, basal linear deposits; BrM, Bruch’s membrane; RPE, retinal pigment epithelium.CC BY · PubMed Central
Figure 1 Complement diffusion through BrM. BrM has been shown to act as a barrier between the retina and choroid, allowing a limited number of complement proteins, such as FHL-1, factor D, and C5a, to diffuse through. This compartmentalisation may be exacerbated in ageing and disease, as lipid deposition in AMD has been shown to reduce FHL-1 diffusion. This could create two separate compartments for complement activation and regulation, namely the retinal and choroidal sides, with complement proteins remaining on their side of origin. Abbreviations: FHL-1, Factor H-like 1 protein; RPE, retinal pigment epithelium.
Figure 1 Complement diffusion through BrM. BrM has been shown to act as a barrier between the retina and choroid, allowing a limited number of complement proteins, such as FHL-1, factor D, and C5a, to diffuse through. This compartmentalisation may be exacerbated in ageing and disease, as lipid deposition in AMD has been shown to reduce FHL-1 diffusion. This could create two separate compartments for complement activation and regulation, namely the retinal and choroidal sides, with complement proteins remaining on their side of origin. Abbreviations: FHL-1, Factor H-like 1 protein; RPE, retinal pigment epithelium.CC BY · PubMed Central
Figure 2 Age-related changes to BrM. With increasing age, BrM undergoes several alterations, including overall thickening due to increased deposition of collagen, lipids, TIMP-2, MMPs 2 and 9, calcium phosphate, and AGEs. Additionally, basal laminar and basal linear deposits are observed with age, and there is a reduction in heparan sulphate. These changes to BrM contribute to the pathogenesis of several retinal diseases, including age-related macular degeneration. Abbreviations: TIMP, tissue inhibitor of metalloproteinase; MMP, matrix metalloproteinase; AGEs, advanced glycation end-products; RPE, retinal pigment epithelium; CEC, choroidal endothelial cell.
Figure 2 Age-related changes to BrM. With increasing age, BrM undergoes several alterations, including overall thickening due to increased deposition of collagen, lipids, TIMP-2, MMPs 2 and 9, calcium phosphate, and AGEs. Additionally, basal laminar and basal linear deposits are observed with age, and there is a reduction in heparan sulphate. These changes to BrM contribute to the pathogenesis of several retinal diseases, including age-related macular degeneration. Abbreviations: TIMP, tissue inhibitor of metalloproteinase; MMP, matrix metalloproteinase; AGEs, advanced glycation end-products; RPE, retinal pigment epithelium; CEC, choroidal endothelial cell.CC BY · PubMed Central
Figure 4 Comparison of OCT images of younger and older retinas. (A,B) show scanning laser ophthalmoscope fundal images and corresponding horizontal 15-degree OCT line scans of a 26-year-old female with a clear lens and an 86-year-old female who had undergone cataract surgery. The OCT images were averaged from 100 B-scans. (C,D) show high magnification views of the outer retina. In the 26-year-old individual, clear distinctions can be made between the IZ, RPE, BrM, and CC. However, in the 86-year-old individual, these structures are indistinct, and there is apparent thickening of BrM and thinning of the CC. Abbreviations: BrM, Bruch’s membrane; CC, choriocapillaris; ELM, external limiting membrane; EZ, ellipsoid zone; IZ, interdigitation zone; OCT, optical coherence tomography; RPE; retinal pigment epithelium.
Figure 4 Comparison of OCT images of younger and older retinas. (A,B) show scanning laser ophthalmoscope fundal images and corresponding horizontal 15-degree OCT line scans of a 26-year-old female with a clear lens and an 86-year-old female who had undergone cataract surgery. The OCT images were averaged from 100 B-scans. (C,D) show high magnification views of the outer retina. In the 26-year-old individual, clear distinctions can be made between the IZ, RPE, BrM, and CC. However, in the 86-year-old individual, these structures are indistinct, and there is apparent thickening of BrM and thinning of the CC. Abbreviations: BrM, Bruch’s membrane; CC, choriocapillaris; ELM, external limiting membrane; EZ, ellipsoid zone; IZ, interdigitation zone; OCT, optical coherence tomography; RPE; retinal pigment epithelium.CC BY · PubMed Central
Figure 5 The pathways of the complement system. The complement system is a network of proteolytic pathways that work together to maintain the body’s homeostasis. The alternative pathway is continuously activated through the hydrolysis of C3 to C3(H2O) in a process known as “tick-over” and triggers the formation of C3 convertases (C4b:C2b, C3b:Bb (not shown)) and C5 convertases (C4b:C2b:C3b and C3b:Bb:C3b), leading to the production of anaphylatoxins, effector molecules, and the C5b-9 complex (MAC). Although it causes significant inflammation, cell lysis as a result of the MAC is a rare occurrence. Importantly, the production of C3b results in further C3 activation through the formation of the C3b:Bb convertase (also not shown) in a process known as the amplification loop. These pathways are regulated by various factors and cofactors that interact with complement components, activating enzymes, or each other. FH plays a critical role as a cofactor for FI by binding C3b and possessing cofactor/decay-accelerating activities that inhibit the alternative pathway amplification loop and initiate the breakdown pathway of C3b. Abbreviations: FH, Factor H; FI, Factor I; MAC, membrane attack complex; PAMP, pathogen-associated molecular pattern.
Figure 5 The pathways of the complement system. The complement system is a network of proteolytic pathways that work together to maintain the body’s homeostasis. The alternative pathway is continuously activated through the hydrolysis of C3 to C3(H2O) in a process known as “tick-over” and triggers the formation of C3 convertases (C4b:C2b, C3b:Bb (not shown)) and C5 convertases (C4b:C2b:C3b and C3b:Bb:C3b), leading to the production of anaphylatoxins, effector molecules, and the C5b-9 complex (MAC). Although it causes significant inflammation, cell lysis as a result of the MAC is a rare occurrence. Importantly, the production of C3b results in further C3 activation through the formation of the C3b:Bb convertase (also not shown) in a process known as the amplification loop. These pathways are regulated by various factors and cofactors that interact with complement components, activating enzymes, or each other. FH plays a critical role as a cofactor for FI by binding C3b and possessing cofactor/decay-accelerating activities that inhibit the alternative pathway amplification loop and initiate the breakdown pathway of C3b. Abbreviations: FH, Factor H; FI, Factor I; MAC, membrane attack complex; PAMP, pathogen-associated molecular pattern.CC BY · PubMed Central
Figure 6 Figure 6. Different types of drug delivery route in the human eye. Intravitreal (IVT) injections are a common method of administering therapeutic agents to the eye. Other routes of administration, such as subretinal and suprachoroidal injections, are also being investigated. Subretinal agents may be administered transvitreally or by cannulation through the suprachoroidal space. Viral gene therapies targeting the retina vary in their vector distribution, retinal tropism, and transduction efficiency depending on the route of delivery used. While efficacy is a primary focus, safety is also a key consideration, as it relates to inflammation and iatrogenic complications. Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; RPE, retinal pigment epithelium.
Figure 6 Figure 6. Different types of drug delivery route in the human eye. Intravitreal (IVT) injections are a common method of administering therapeutic agents to the eye. Other routes of administration, such as subretinal and suprachoroidal injections, are also being investigated. Subretinal agents may be administered transvitreally or by cannulation through the suprachoroidal space. Viral gene therapies targeting the retina vary in their vector distribution, retinal tropism, and transduction efficiency depending on the route of delivery used. While efficacy is a primary focus, safety is also a key consideration, as it relates to inflammation and iatrogenic complications. Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; RPE, retinal pigment epithelium.CC BY · PubMed Central

Verification

Claims the paper makes

32 Valid · 5 Not valid · 95 Not checked · 20 Own results and interpretations

95 more claims · 19 with their cited sources checked

Create a free account to see all 152 claims and to verify the 174 references still open.

See all claims — free account
  • Probably not a substantial claim. 16
  • It may state two separate claims as one. 40

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

1 retracted

Show all 321 references

Research works printed but not linked: 3

  1. Hogan, M.J., Alvarado, A.J., and Weddell, J.E. (1971). Histology of the Human. Eye: An. Atlas and Textbook, Saunders.
  2. Johnson, M., and Curcio, C.A. (2012). Structure, Function, and Pathology of Bruch’s Membrane, Elsevier.
  3. Gamlin, P.D., Alexander, J.J., Boye, S.L., Witherspoon, C.D., and Boye, S.E. (2019). Adeno-Associated Virus Vectors. Methods in Molecular Biology, Humana Press.

Cited by

See all 50

Metadata

Authors
Hammadi, S., Tzoumas, N., Ferrara, M., Meschede, I. P., Lo, K., Harris, C., Lako, M., & Steel, D. H.
Affiliations
  • Newcastle University (GB)
  • Sunderland Eye Infirmary (GB)
  • Manchester Royal Eye Hospital (GB)
  • Gyroscope Therapeutics Limited, a Novartis Company, Rolling Stock Yard, 6th Floor, 188 York Way, London N7 9AS, UK
Corresponding author
Steel, David H.
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2023-04-14
Volume
12
Issue
8
Pages
2870
ISSN
2077-0383 (ISSN-L)
OpenAlex
W4365514215
Cited by
44
References
321
Citations by year
2026: 15 · 2025: 16 · 2024: 8 · 2023: 5
FWCI
2.24
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by)
Funders
  • Newcastle University (ACF-2021-01-008, #GR602, #GR601)
  • Gyroscope Therapeutics, a Novartis company (ACF-2021-01-008, #GR602, #GR601)
  • NIHR Academic Clinical Fellowship (ACF-2021-01-008, #GR602, #GR601)
  • Retina UK (ACF-2021-01-008, #GR602, #GR601)
  • Macular Society UK (ACF-2021-01-008, #GR602, #GR601)
  • companies developing complement therapeutics (ACF-2021-01-008, #GR602, #GR601)
  • Gyroscope Therapeutics (a Novartis company) (relevant to work under consideration), Alcon, Boehringer Ingelheim, Bayer, DORC, and Roche (ACF-2021-01-008, #GR602, #GR601)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
Bruch's membrane, age-related macular degeneration, complement system, complement activation, complement inhibitors, retinal pigment epithelium, choriocapillaris, gene therapy, drug delivery routes, intravitreal delivery, subretinal delivery, systemic drug delivery, in vivo imaging, AMD pathogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration. https://app.cochat.ai/papers/10.3390/jcm12082870
The paper
Hammadi, S., Tzoumas, N., Ferrara, M., Meschede, I. P., Lo, K., Harris, C., Lako, M., & Steel, D. H. (2023). Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration. Journal of Clinical Medicine. https://doi.org/10.3390/jcm12082870

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.